HeartSciences furnishes quarterly update via 8-K

HeartSciences Inc. filed a current report to furnish a press release covering its financial and operating results for the quarter ended July 31, 2025, along with other business updates.

Rhea-AI Filing Summary

HeartSciences Inc. filed a current report to furnish a press release covering its financial and operating results for the quarter ended July 31, 2025, along with other business updates. The press release is included as Exhibit 99.1 and is incorporated by reference in this report. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HeartSciences (HSCSW) disclose in this 8-K filing?

HeartSciences Inc. disclosed that it issued a press release providing financial and operating results for the quarter ended July 31, 2025, along with other business updates, and furnished that release as Exhibit 99.1.

Which period does HeartSciences’ latest financial update cover?

The financial and operating results discussed by HeartSciences in the furnished press release cover the quarter ended July 31, 2025.

How are the results and press release treated under securities laws in this 8-K?

The company states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, so it is not subject to Section 18 liability of the Exchange Act and is not incorporated into other filings unless specifically referenced.

What exhibit is attached to HeartSciences’ 8-K for the quarterly results?

Exhibit 99.1 to the 8-K is the press release dated September 11, 2025, which contains HeartSciences’ financial and operating results and other business updates.

Who signed the HeartSciences 8-K related to the quarterly results?

The report was signed on behalf of HeartSciences Inc. by Andrew Simpson, who is President, Chief Executive Officer and Chairman of the Board of Directors.

Does the 8-K itself include detailed financial statements for HeartSciences?

The 8-K indicates that detailed financial and operating results are contained in the press release furnished as Exhibit 99.1, rather than in the body of the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:28 PM Learn about SEC filing dates

false00014684920001468492us-gaap:WarrantMember2025-09-112025-09-1100014684922025-09-112025-09-110001468492us-gaap:CommonStockMember2025-09-112025-09-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its Charter)

Texas			001-41422	26-1344466
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
550 Reserve Street, Suite 360
Southlake, Texas				76092
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 682 237-7781

n/a

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		HSCS		The Nasdaq Stock Market LLC
Warrants		HSCSW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On September 11, 2025, HeartSciences Inc. (the “Company”) issued a press release providing information regarding the Company’s financial and operating results for the quarter ended July 31, 2025, and other business updates. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.

The information contained in Item 2.02 of this Current Report and Exhibit 99.1 to this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1*		Press Release dated September 11, 2025
Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			HEARTSCIENCES INC.
Date:	September 11, 2025	By:	/s/ Andrew Simpson
			Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors